Back to top
more

Aurinia Pharmaceuticals (AUPH)

(Delayed Data from NSDQ)

$5.03 USD

5.03
785,660

-0.06 (-1.18%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $5.03 0.00 (0.00%) 7:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of -5.56% and 3.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?

by Zacks Equity Research

Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Journey Medical (DERM) stock now may turn out to be a prudent move.

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical

by Zacks Equity Research

Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year

by Kinjel Shah

Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.

Can Aurinia (AUPH) Climb 46.13% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 46.1% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aurinia Pharmaceuticals (AUPH) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Wall Street Analysts See a 59.35% Upside in Aurinia (AUPH): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Aurinia (AUPH) points to a 59.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?

by Zacks Equity Research

Here is how Aurinia Pharmaceuticals (AUPH) and Creative Medical Technology Holdings, Inc. (CELZ) have performed compared to their sector so far this year.

Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of 47.06% and 41.94%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Is it a Good Idea to Invest in Dynavax (DVAX) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Dynavax Technologies (DVAX) stock now may turn out to be a prudent move.

Merck (MRK) Gets CHMP Nod for Expanded Use of Antiviral Drug

by Zacks Equity Research

CHMP gives a positive opinion to Merck (MRK) for the expanded use of Prevymis to help prevent CMV disease in high-risk kidney transplant patients.

J&J (JNJ) Beats Q3 Earnings & Sales Estimates Post Spin-Off

by Zacks Equity Research

J&J (JNJ) beats estimates for third-quarter earnings and sales. It raises full-year sales and earnings guidance.

Pfizer (PFE) Cuts 2023 Outlook as COVID Products' Demand Falls

by Zacks Equity Research

Pfizer (PFE) lowers its total revenue guidance for 2023 by $9 billion as sales from its COVID products, Comirnaty vaccine and Paxlovid pill decline.

Lilly (LLY) Up on NVO's Ozempic Early Success in Kidney Study

by Zacks Equity Research

Eli Lilly's (LLY) Mounjaro is also being evaluated in clinical studies for patients who are obese or overweight and have CKD. Investors are probably expecting similar success with Mounjaro's CKD study.

Amgen's (AMGN) Stock Rallies Almost 5% on Broker Upgrade

by Zacks Equity Research

A Leerink Partner analyst expects accelerating pipeline news flow for Amgen (AMGN).

Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit

by Zacks Equity Research

Merck's (MRK) phase III study on Keytruda shows a statistically significant overall survival benefit for patients with stage II, IIIA or IIIB NSCLC.

J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC

by Zacks Equity Research

J&J (JNJ) files an application in Europe seeking expanded approval for Rybrevant as a first-line combination treatment in patients with advanced or metastatic EGFR exon 20 insertion mutation-positive NSCLC.

AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker

by Zacks Equity Research

AbbVie's (ABBV) buyout of Mitokinin, which is making a novel treatment for Parkinson's Disease (PD), if successfully closed, is likely to strengthen its neuroscience pipeline.

AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M

by Zacks Equity Research

AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.

Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection

by Zacks Equity Research

Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.

Are Medical Stocks Lagging Align Technology (ALGN) This Year?

by Zacks Equity Research

Here is how Align Technology (ALGN) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.